Cancer types · Other solid tumours
Sarcomas
Sarcomas are rare cancers of connective tissues, such as muscle, fat, bone and blood vessels. There are more than 70 subtypes, and each behaves differently.
Molecular testing is often part of making the diagnosis, because many subtypes are defined by specific gene fusions or amplifications. Review by an experienced sarcoma pathologist is especially important.
Clinical and molecular questions that often arise
- Is the subtype confirmed, including by molecular testing where needed?
- Has expert sarcoma pathology review been obtained?
- For GIST, what are the KIT and PDGFRA results?
- Are there trials for the specific subtype?
Information that may be part of an individual assessment
- Imaging, often MRI for soft-tissue and limb tumours.
- Core biopsy planned with the surgical team.
- Histopathology with immunohistochemistry.
- Molecular tests such as FISH or sequencing for fusions and amplifications.
Which investigations are appropriate is decided by the treating team for each person.
Molecular profiling and biomarker interpretation
Depending on the setting, molecular and biomarker questions in sarcomas may involve:
- Subtype-defining fusions (for example SS18–SSX, EWSR1 and FUS rearrangements)
- MDM2 amplification
- KIT and PDGFRA mutations in GIST
- NTRK and ALK fusions
- TP53 alterations
Biomarkers, panels and available tests vary by subtype, disease setting, assay and guideline version. A detected alteration is not automatically actionable.
How KPCIRC pathways may apply
POAS
POAS may help interpret a sarcoma molecular report and clarify which alterations are diagnostic, which carry therapeutic evidence and which are uncertain.
Molecular Tumour Board
MTB review is often valuable because rarity, subtype diversity and multimodality treatment benefit from several specialist perspectives.
Second opinion and progression review
A second opinion, including pathology review, may help clarify diagnosis and surgical planning.
Hereditary risk and screening
Some sarcomas are associated with inherited conditions such as Li-Fraumeni syndrome (TP53), neurofibromatosis type 1 and hereditary retinoblastoma. Young age or a strong family history may prompt genetics assessment.
How to access the relevant pathway
Patients and families
- Talk to your treating oncologist about whether an additional review may help.
- Request a consultation and tell us which question you want answered.
- Share records only when asked, through the secure route.
Referring doctors
- Define the clinical question and the pathway: POAS, MTB, second opinion or progression review.
- Start a case enquiry without patient identifiers.
- Scope, fees and timing are confirmed before any review proceeds.
Questions and limitations
Why might my biopsy be sent for another opinion?
Because sarcomas are rare and diverse, expert review helps confirm the subtype, which shapes everything that follows.
Is a fusion result a treatment target?
Sometimes it is diagnostic only; occasionally, as with NTRK fusions, it has therapeutic relevance. The distinction matters.
Does this page apply to my situation?
This page is educational. It explains common questions but cannot account for individual circumstances. Your treating clinician is best placed to interpret your reports and plan your care.
Educational content reviewed against the KPCIRC service scope. It is not a diagnosis, a treatment recommendation or a statement that a specialist or service is available for this cancer type.